Effect of nivolumab alone and combined with anlotinib in treatment of elderly patients with advanced gastric cancer
CSTR:
Author:
Affiliation:

(Department of Pharmacy, Xuzhou Cancer Hospital, Xuzhou Third People′s Hospital, Xuzhou 221005, Jiangsu Province, China)

Clc Number:

Fund Project:

This work was supported by the Medical Education Collaborative Innovation Fund of Jiangsu University (JDYY2023047).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Objective To explore the effect of nivolumab combined with anlotinib in the treatment of elderly advanced gastric cancer. Methods A total of 120 elderly patients with advanced gastric cancer who received third-line treatment in our hospital from January 2021 to January 2023 were enrolled, and 60 of them received nivolumab treatment (single drug treatment group), and the other 60 ones received nivolumab combined with anlotinib treatment (combined treatment group). After four continuous courses of treatment, the objective remission rate (ORR) and disease control rate (DCR) were calculated. The peripheral blood levels of vascular endothelial growth factor A (VEGF-A), carcinoembryonic antigen (CEA), matrix metalloproteinase-2 (MMP-2) and MMP-9 and the percentages of peripheral blood T lymphocyte subsets were detected before and after treatment. The occurrence of adverse reactions was observed. SPSS statistics 22.0 was used for data analysis, and t test or Chi-square test was employed for between-group comparison depending on data type. Kaplan-Meier survival analysis was applied to analyze the cumulative survival rate of each group, and Log-rank test was conducted to analyze the difference in survival rate between the two groups. Results The DCR and ORR in the combined treatment group was 76.67% (46/60) and 43.33% (26/60), which were higher than those of the single drug treatment group [58.33% (35/60) and 25.00% (15/60), P<0.05]. After treatment, the combined treatment group had significantly lower serum VEGF-A, CEA, MMP-2 and MMP-9 levels, higher percentages of CD3+, CD4+ T cells and CD4+/CD8+ ratio, but lower percentage CD8+ T cells when compared to the single drug treatment group (P<0.05). There was no statistical difference in occurrence of adverse reactions between the two groups (P>0.05). The patients were followed up until February 2024, and the results showed that in the combined treatment group and single drug treatment group, the median progression-free survival (PFS) was 6.10 months (95%CI 4.607-7.593) and 4.00 months (95%CI 3.059-4.941), and the median overall survival (OS) was 9.25 months (95%CI 8.394-10.099) and 6.19 months (95%CI 5.583-6.789), respectively, with statistical differences between them (χ2=6.298,4.943, P<0.05). Conclusion Nivolumab combined with anlotinib, as a third-line treatment regimen, can effectively prolong the survival time and improve the tumor control effect in elderly patients with advanced gastric cancer. However, its efficacy needs to be further verified by multi-center, large-sample prospective studies.

    Reference
    Related
    Cited by
Get Citation
Related Videos

Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 14,2024
  • Revised:
  • Adopted:
  • Online: June 25,2025
  • Published:
Article QR Code